The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| QNTM | +79.83% | -95.67% | -46.63% | -99% |
| S&P | +13.66% | +78.98% | +12.35% | +147% |
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.
Most marijuana stocks fell last month, but these were the worst of the worst.
All six of these cannabis stocks lost at least a third of their value.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$145.34K | -20.3% |
| Market Cap | $44.46M | 498.6% |
| Market Cap / Employee | $6.35M | 0.0% |
| Employees | 7 | 0.0% |
| Net Income | -$4,747.60K | -18.2% |
| EBITDA | -$4,512.86K | -14.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $445.94K | -85.7% |
| Inventory | 0.1 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $2.56M | 585.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -171.84% | -116.6% |
| Return On Invested Capital | -97.90% | -6.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,728.80K | 50.0% |
| Operating Free Cash Flow | -$1,728.80K | 50.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.42 | 1.54 | 9.58 | 7.76 | 2813.60% |
| Price to Tangible Book Value | 0.61 | 2.71 | 60.84 | 49.27 | 9716.50% |
| Enterprise Value to EBITDA | -0.01 | -3.97 | -11.55 | -12.95 | -1515.26% |
| Return on Equity | -114.9% | -235.1% | -367.0% | -228.6% | 239.03% |
| Total Debt | $824.92K | $1.28M | $2.27M | $2.56M | 585.50% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
